Cholangiocarcinoma can arise in bile ducts inside the liver or in larger ducts outside it, and treatment depends heavily on exact location, stage, vascular involvement, biliary obstruction, liver function and whether complete surgical removal is realistic. German hepatobiliary centers publish multidisciplinary pathways involving gastroenterology/endoscopy, liver and biliary surgery, medical oncology, radiology, pathology and radiation oncology. International patients should therefore request a hepatobiliary tumor-board review rather than assuming that every bile duct cancer follows the same operation or drug pathway.
First define where the bile duct cancer starts
Intrahepatic, perihilar and distal cholangiocarcinomas differ anatomically and can require different staging and surgical strategies. Charité explicitly distinguishes cancers within and outside the liver, while Heidelberg groups cholangiocarcinoma within a specialist hepatobiliary program. The exact site should be clear in the referral documents before a German center proposes treatment.
Biliary obstruction may need treatment before definitive cancer therapy
Bile duct tumors can obstruct bile flow and cause jaundice, itching or cholangitis. Charité's endoscopy service documents ERCP, cholangioscopy, tissue sampling and biliary stenting as part of its biliary-care spectrum. Drainage strategy should be coordinated with the surgical and oncology plan because repeated procedures or poorly positioned stents can complicate later treatment.
Resectability is a specialist hepatobiliary-surgery question
Surgery offers the main curative-intent option for selected localized cholangiocarcinoma, but feasibility depends on tumor location, liver reserve, vascular involvement and whether a complete resection can be achieved. Heidelberg and Charité both integrate hepatobiliary surgery within multidisciplinary care. A German review should therefore assess the full cross-sectional imaging before travel.
Pathology and molecular testing can affect treatment
Charité notes that molecular genetic analysis can identify actionable alterations in a subset of patients. In advanced disease, expert pathology and current molecular profiling can influence targeted-treatment options and clinical-trial eligibility. Ask the German center whether existing tissue is sufficient or whether additional slides, blocks or biopsy material are needed.
Systemic treatment is central when surgery is not possible
Charité documents combined chemotherapy and immunotherapy for many unresectable bile duct cancers, with targeted therapy possible in selected molecularly defined cases. The exact regimen depends on disease location, prior treatment, molecular findings, liver function and current approvals, so a specialist recommendation is more useful than a static drug list.
Radiation and local treatments are selected multidisciplinary options
Heidelberg's Liver Cancer Center brings radiation oncology and interventional radiology into hepatobiliary tumor-board planning. Local treatment can be relevant in selected cases, but it should be positioned within the wider disease strategy rather than promoted as a universal alternative to surgery or systemic therapy.
Perihilar tumors can require especially complex surgical planning
Tumors near the hepatic hilum may involve major bile ducts and blood vessels and can require extensive liver and bile-duct surgery. International patients should send high-quality CT or MRI before travel so the hepatobiliary team can assess anatomy, future liver remnant and whether additional drainage or vascular planning is required.
Records to send before travelling
A useful German hepatobiliary review should allow the team to define location, stage, biliary obstruction and prior treatment before proposing a visit.
- Contrast-enhanced CT and/or MRI/MRCP in DICOM format
- Radiology reports describing intrahepatic, perihilar or distal location
- ERCP, cholangioscopy or biliary-drainage reports when already performed
- Pathology or cytology reports and slides/blocks if available
- Liver laboratory results including bilirubin and cholestatic markers
- Previous surgery, stent, drainage, chemotherapy or radiotherapy details
- Molecular profiling results when already available
- Current medication and relevant liver or infectious history
- A clear question about resection, drainage, systemic treatment, molecular therapy or second opinion
Plan for biliary infections and follow-up
Patients with biliary obstruction or stents can have recurrent cholangitis and may need urgent local care. Before returning home, clarify stent-management plans, laboratory monitoring, imaging intervals and when the German hepatobiliary team wants the case re-reviewed.
Sources and review
This guide was last source-reviewed on 2026-08-30.
- Bile Duct Cancer – diagnosis and treatment — Charité – Universitätsmedizin Berlin ↗
- Endoscopy Center – ERCP, cholangioscopy and biliary stenting — Charité – Universitätsmedizin Berlin ↗
- Liver / Gallbladder Cancer – NCT Heidelberg — NCT Heidelberg / Heidelberg University Hospital ↗
- Liver Cancer Center Heidelberg – hepatobiliary tumor clinic — Heidelberg University Hospital ↗
- Clinical pathways – malignant biliary tumors — University Medical Center Freiburg ↗